Standout Papers

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria 2022 2026 2023 202489
  1. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria (2022)
    Marcus Maurer, William Berger et al. Journal of Allergy and Clinical Immunology

Immediate Impact

2 from Science/Nature 62 standout
Sub-graph 1 of 22

Citing Papers

Remibrutinib in Chronic Spontaneous Urticaria
2025 Standout
Revolutionizing core muscle analysis in female sexual dysfunction based on machine learning
2024 Standout

Works of William Berger being referenced

Instruments for assessing sexual dysfunction in Arabic: A systematic literature review
2022
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
2022 Standout

Author Peers

Author Last Decade Papers Cites
William Berger 18 885 732 406 25 1.2k
James A. McLean 14 1125 487 849 22 1.6k
James H. Day 22 828 1132 160 44 1.4k
Walter T. Kaltenborn 86 797 380 782 23 1.6k
Clifton T. Furukawa 13 634 306 560 54 1.4k
Maritta Kilpeläinen 8 785 319 599 41 1.4k
J O Warner 2 703 313 556 31 1.2k
J Montoro 7 568 747 117 44 1.2k
Jeremy Roberts 17 583 344 279 20 1.1k
K. M. Latimer 28 1164 268 931 20 1.4k
Philip Lieberman 1 552 1116 101 18 1.5k

All Works

Loading papers...

Rankless by CCL
2026